Lower RM costs, operating leverage drive earnings

Company
12 Aug 2024
5 Min read 
  • ALKEM Laboratories 1QFY25 Results Update in Healthcare sector
  •  Financials & Valuation: Sales, EBITDA, Adj. PAT, Ratios, Valuations
  •  Shareholding pattern: Promoter, DII, FII, Others
  •  Highlights from the management commentary: R&D, EBITDA margin guidance, growth initiatives
  •  Controlled costs propel profit growth: Revenue, Gross margin, EBITDA margin, Adj. PAT
  •  Product development, organizational changes to improve business prospects: DF, US, Maintain Neutral
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities